TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Rate of patients who remain in clinical trial to trial completion
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Change in GerdQ score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Change in proportion of GERD symptoms absence
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Patient experience with Distress Thermometer
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change in the score of fall risk test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in the Overall Stability Index
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time of Control for Limit of Stability Test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: complications related to intubation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cellular AD biomarkers
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Barrier biomarkers
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: half-life of plasma concentrations of dexamethasone
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: maximum plasma concentration of dexamethasone
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: area under the concentration-time curve for plasma dexamethasone
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Safety and tolerability of CB03-154
Endpoint domain: Adverse events/effects
Primary endpoint: Proportion of eyelids with erythema
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Sensitivity and specificity of visual assessment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sensitivity of Biomarkers
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: TBR threshold
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: rate of MACE
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: PDL size after 3 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of Severe Oral mucositis (WHO grade ≥3)
Endpoint domain: Adverse events/effects
Primary endpoint: Time to onset of Severe Oral mucositis (WHO grade ≥3)
Endpoint domain: Adverse events/effects
Primary endpoint: Duration of Severe Oral mucositis (WHO grade ≥3)
Endpoint domain: Adverse events/effects
Primary endpoint: Latency and amplitude of the H-reflex
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Muscle spasticity levels as assessed by the Modified Ashworth Scale (MAS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Skin microcirculation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Sequestered salt content (SSC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: neuropsychiatric clinical scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Bioavailability based on AUC
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Binocular uncorrected distant visual acuity (bUDVA)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Binocular uncorrected intermediate reading acuity (bUIRA)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Binocular uncorrected near reading acuity (bUNRA)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Major congenital malformation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Maximum Observed Serum Concentration (Cmax) of Lutikizumab
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to Cmax (Tmax) of Lutikizumab
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from Baseline in Absolute neutrophil count at 1 year
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Number and proportion of patients experiencing SMA-related symptoms prior to initiation of the first DMT
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean age at onset of SMA-related symptoms experienced prior to initiation of the first DMT
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean age at SMA genetic diagnosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Technical success of ESD under SA
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Safety of ESD under SA
Endpoint domain: Adverse events/effects
Primary endpoint: failure rate of S-ICD screening
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: inappropriate shock event
Endpoint domain: Adverse events/effects
Primary endpoint: Emotional Stress - Hair
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Emotional Stress - Saliva
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: BOLD activation to cigarette cues
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Receipt of >1 COVID-19 vaccine or booster dose
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence of postnatal depression
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of persistent postpartum pain (PPP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Best Complete response (CR) rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Frequency of dose-limiting toxicities
Endpoint domain: Adverse events/effects
Primary endpoint: Vaginal microbial community composition
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Vaginal metabolic profile
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Vaginal immunological profile
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Suicidal ideation and behavior
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Classification of diabetes subtypes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Total morphine equivalent
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in total limb swelling
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: overall Hb response rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Peak change from baseline
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Intervention dosage
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of unexpected adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Participants' acceptance and degree of satisfaction
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: ADHD-RS-5 inattention sub-scale
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Incidence of bleeding and clotting complications
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Unplanned hospitalisation
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: incremental area under the curve of postprandial glucose response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in severity of EDS
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Total survival
Endpoint domain: Mortality/survival
Primary endpoint: Proportion of participants that achieve clinical benefit
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: number of patients weaned from ventilators
Endpoint domain: Mortality/survival
Primary endpoint: number of patients discharged from ICU
Endpoint domain: Mortality/survival
Primary endpoint: Postoperative quality of recovery score 15 (Qor-15Ar)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: CD4 expression
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: CD25 expression
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: IL17 expression
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Serum Sodium Level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Proportion of patients with modified Rankin Score 0-2
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in UACR (urinary albumin-to-creatinine ratio)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Area under the plasma concentration versus time curve (AUC) of berberine incorporated in gamma-cyclodextrin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area under the plasma concentration versus time curve (AUC) of berberine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: duration of port site closure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Rate of failure of port site
Endpoint domain: Adverse events/effects
Primary endpoint: Target-vessel Myocardial infarction (TV-MI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Subjective Soreness Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Decrease of Analgesic requirement for pain control
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Kyphotic Angle
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Integrated gastric acidity (% Decrease from baseline)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: histological complete resection
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Change in total biliary volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of access site related BARC type III or V bleeding
Endpoint domain: Adverse events/effects
Primary endpoint: Proportion of patients relieved
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUC-ROC of the CathEF algorithm for LVEF differentiation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Proportion of patients receiving optimized antibiotic therapy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Number of SARS-CoV-2 sequences generated
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change From Baseline in Sinonasal Outcome Test -22 (SNOT-22) Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change From Baseline in endoscopic Nasal polyp score of nasal cavity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in endurance exercise performance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Unified Parkinson's Disease Rating Scale (MDS-UPDRS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Aspirin Use Proportion
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Change in plasma nicotine concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change of maximal voluntary activation (VA)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change muscle electromyography
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change of Rate of Perceived Exertion RPE
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: HCC screening positive
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Rate of ADA enzyme deficiency
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Classification of ATFL injury
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Tmax of tegoprazan
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Prevention of Covid-19 infection
Endpoint domain: Adverse events/effects
Primary endpoint: Melasma severity index
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Proportion of patients alive and free of dialysis at 3 years
Endpoint domain: Mortality/survival
Primary endpoint: FDHT total receptor expression (TRE) volume parameters
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: CTC count before and after treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: ctDNA abundance before and after treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Recurrence rate of inguinal hernia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Numerical rating score of pain
Endpoint domain: Life impact
Endpoint subdomain: Pain
Primary endpoint: Percentage of participants reporting adverse events (AEs) through 4 weeks following investigational product administration
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of participants reporting serious adverse events (SAEs) through 6 months following investigational product administration
Endpoint domain: Adverse events/effects
Primary endpoint: The difference in percentage of participants achieving seroconversion at 4 weeks after vaccination in Influenza and COVID-19 combination B recipients compared to licensed influenza vaccine recipients
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Early diagnosis of pre-eclampsia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: Esophageal pressure-time product per minute (PTPes/min)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Frequency of Perceived Discrimination Experiences
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Recent Discrimination and Perceived Ethnic Discrimination Score
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Recent and Lifetime Discrimination Stress Score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Speech understanding
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Value of the angle Kappa
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Value of the angle Alpha
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in FIB-4 score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Liver outcomes
Primary endpoint: Occupational Self-Assessment (OSA)
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: World Health Organization Disability Assessment Schedule 2 (WHO-DAS II)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Headache Impact Test-6
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Self-Reported 7-Day Point Prevalence Abstinence Rate at Month 6
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clinical outcome after correction of hallux valgus deformity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Number of patients presenting with Invasive Meningococcal infection
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Proportion of participants requesting CRC screening test
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Area Under the Plasma Concentration-Time Profile (AUClast)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of augmented renal clearance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Infectivity of N. gonorrhoeae inoculum
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Development of grade 3-4 neutropenia
Endpoint domain: Adverse events/effects
Primary endpoint: Development of neutropenic fever
Endpoint domain: Adverse events/effects
Primary endpoint: surveillance rate
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: State-Trait Anxiety Inventory Trait (STAI-T)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Adult Emotion Regulation
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Changes in adult responses to child emotions
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Percentage time spent in the euglycaemic range specific for pregnancy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Regions of pathologically increased tracer uptake
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Health-related quality of life (cancer specific)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Box And Block
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Assisting hand Assessment scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Specific immune responses to vaccines
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: 3D plaque score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Paris Functional Coccydynia Questionnaire
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Nitric oxide (NO)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Catalase (CAT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Glutathione (GSH)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in EEG source localized pDMN alpha activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: PK and PD responses to L-citrulline
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum Observed Plasma Concentration (Cmax) of Midazolam and 1-hydroxymidzolam
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area Under the Plasma Concentration-time Curve from Time 0 to Time of the Last Observed Quantifiable Concentration (AUC[0-last]) of Midazolam and 1-hydroxymidzolam
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area Under the Plasma Concentration-time Curve from Time 0 to Infinite time (AUC[0-infinity]) of Midazolam and 1-hydroxymidzolam
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum Observed Plasma Concentration (Cmax) of Ethinylestradiol and Drospirenone
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Kinematic measurement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Subjective functional mobility
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Alzheimer's Disease Assessment Scale-Cognitive (ADAS-Cog)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Swallowing-Quality of Life
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Prevalence of mortality
Endpoint domain: Mortality/survival
Primary endpoint: Heart rate variability (RMSSD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Plantar pressure centers
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Molecular changes in COPD
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Generalised Anxiety Disorder (GAD-7) change
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Patient Health Questionnaire (PHQ-9) change
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Percentage of diagnosed PWH in treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of participants with recurrent stroke within one year of follow-up period
Endpoint domain: Mortality/survival
Primary endpoint: New injury
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in serum anti-dsDNA antibody titers
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Best complete remission rate (CR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: cardiac stroke volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Best-corrected distance visual acuity (BCDVA)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: time to loss of palpebral reflex
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time for BIS decrease < 60
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes